Communiqués CNS Pharmaceuticals, Inc.

Actions

CNSP

US18978H3003

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/07/2024			Varia. 5j.	Varia. 1 janv.
1,18 ^USD	-4,07 %		+1,72 %	-98,14 %

15/07	CNS Pharmaceuticals dépose un prospectus pour la vente d'un maximum de 2,4 millions d'actions par les actionnaires	MT
09/07	CNS Pharmaceuticals se conforme de nouveau à la règle du prix minimum de l'offre du Nasdaq	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement	04/07	AQ
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement	27/06	AQ
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement	17/06	AQ
CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase	21/05	AQ
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results	17/05	AQ
CNS Pharmaceuticals to Present at the LSX World Congress 2024	24/04	AQ
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break, the CNSP Opportunity	23/04	AQ
CNS Pharmaceuticals to Present at Two Investor Conferences in April	02/04	AQ
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering	30/01	AQ
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors	19/01	AQ
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	18/01	AQ
CNS Pharmaceuticals : Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin - Form 8-K	18/12	PU
How CNS Pharmaceuticals Is Taking a Different Approach to Find a Treatment for Glioblastoma, a Cancer with a Poor Prognosis and No Cure	07/12	AQ
CNS Pharmaceuticals to Release Interim Data by the End of the Year for Potential Glioblastoma Drug Candidate	17/11	AQ
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study before Year End	16/11	AQ
CNS Pharmaceuticals : Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End - Form 8-K	15/11	PU
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference	20/10/23	AQ
CNS Pharmaceuticals : Regulation FD Disclosure - Form 8-K	18/10/23	PU
Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals Innovative Approach to Treatment Could Offer Hope	17/10/23	AQ
CNS Pharmaceuticals Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date	12/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués CNS Pharmaceuticals, Inc.

Actions

CNSP

US18978H3003

Communiqués

Filtres